

Galactosylceramidase

[View the current Galactosylceramidase InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Galactosylceramidase.html)

(<http://www.bioportfolio.com/indepth/Galactosylceramidase.html>)

Galactosylceramidase is an enzyme which removes galactose from ceramide derivatives .



Recent Publications on Galactosylceramidase:

- [Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy.](#)
*Globoid cell leukodystrophy, or Krabbe's disease, is a severe disorder of...*3rd April, 2008
DVM, PhD, Division of Comparative Pathology, Tulane National Primate- Am J Pathol. 2008 Jan;172(1):98-111. Epub 2007 Dec 28. ([DOI Direct Link](#))
- [Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy.](#)
*Globoid-cell leukodystrophy (GLD) is a rapidly progressing inherited...*1st April, 2008
Department of Internal Medicine, Washington University School of Medicine,- Mol Ther. 2007 Jan;15(1):44-52. ([DOI Direct Link](#))
- [Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain.](#)
*A number of studies have shown that a short peptide, the protein...*15th February, 2008
Department of Medicine, Louisiana State University Health Sciences Center,- J Neurochem. 2008 Feb;104(4):1055-64. Epub 2007 Nov 6. ([DOI Direct Link](#))
- [Autonomic denervation of lymphoid organs leads to epigenetic immune atrophy in a mouse model of Krabbe disease.](#)
*Lysosomal beta-galactosylceramidase deficiency results in demyelination...*23rd January, 2008
Department of Anatomy, College of Medicine, University of Illinois at- J Neurosci. 2007 Dec 12;27(50):13730-8. ([DOI Direct Link](#))
- [Peripheral neuropathy in the twitcher mouse: accumulation of extracellular matrix in the endoneurium and aberrant expression of ion channels.](#)
*Globoid cell leukodystrophy (GLD; Krabbe's disease), caused by a genetic...*4th January, 2008
Department of Pathology and Laboratory Medicine, University of North- Acta Neuropathol. 2008 May;115(5):577-87. Epub 2008 Jan 3. ([DOI Direct Link](#))
- [Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy.](#)
*Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a...*6th November, 2007
Mayo Clinic College of Medicine, 4500 San Pablo Rd., Jacksonville, Florida- FASEB J. 2007 Aug;21(10):2520-7. Epub 2007 Apr 2. ([DOI Direct Link](#))
- [Psychosine-induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients.](#)
*Globoid cell leukodystrophy or Krabbe disease (KD), is a hereditary...*28th September, 2007

Department of Neurological and Behavioural Sciences, University of Siena,- J Cell Physiol. 2007 Sep;212(3):737-43. ([DOI Direct Link](#))

- [Molecular beacon genotyping for globoid cell leukodystrophy from hair roots in the twitcher mouse and rhesus macaque.](#)
*Rapid and accurate genotype determination is ideal for the maintenance of...*19th August, 2007
Department of Biology, University of New Orleans, 2000 Lakeshore Drive,- J Neurosci Methods. 2007 Jun 15;163(1):60-6. Epub 2007 Feb 25. ([DOI Direct Link](#))
- [A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania \(Sicily, Italy\) region.](#)
*A high proportion of patients with late onset forms of Krabbe disease is...*25th July, 2007
Center for Medical Genetics, Universitair Ziekenhuis Brussel, Brussels,- Hum Mutat. 2007 Jul;28(7):742. ([DOI Direct Link](#))
- [Diagnosis of Krabbe disease by use of a natural substrate.](#)
*This chapter describes in detail a practical procedure for the preparation...*31st January, 2007
Genetic-Metabolic Laboratory, Department of Pediatric Laboratory Medicine,- Methods Mol Biol. 2006;347:321-30. ([DOI Direct Link](#))
- [Suppression of galactosylceramidase \(GALC\) expression in the twitcher mouse model of globoid cell leukodystrophy \(GLD\) is caused by nonsense-mediated mRNA decay \(NMD\).](#)
*The twitcher mouse is a pathologically and enzymatically authentic model...*9th December, 2006
Department of Pharmacology, Mayo Clinic College of Medicine, Jacksonville,- Neurobiol Dis. 2006 Aug;23(2):273-80. Epub 2006 Jun 8. ([DOI Direct Link](#))
- [Undifferentiated mouse mesenchymal stem cells spontaneously express neural and stem cell markers Oct-4 and Rex-1.](#)
*BACKGROUND: Previous adult stem cells studies have provided evidence that...*25th October, 2006
Department of Neurology, Centre for Immunology, St Vincent's Hospital,- Cytotherapy. 2006;8(3):228-42. ([DOI Direct Link](#))
- [Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation.](#)
*Krabbe disease is an autosomal recessive leukodystrophy. It is...*29th September, 2006
Department of Pediatrics, Osaka University Graduate School of Medicine,- J Hum Genet. 2006;51(6):548-54. Epub 2006 Apr 11. ([DOI Direct Link](#))
- [Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain.](#)
*BACKGROUND: Demyelination in globoid cell leukodystrophy (GLD) is due to a...*22nd September, 2006
Telethon Institute for Gene Therapy, San Raffaele Scientific Institute,- J Gene Med. 2006 Aug;8(8):962-71. ([DOI Direct Link](#))
- [Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy.](#)
*While transplanted neural stem cells (NSCs) have been shown to hold...*12th August, 2006
Department of Animal Science, Faculty of Veterinary Science, University of- J Neurochem. 2006 Jun;97(6):1585-99. ([DOI Direct Link](#))

Galactosylceramidase Patents:



- 5929304- [Production of lysosomal enzymes in plant-based expression systems](#)
- 6730297- [Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders](#)
- 6787321- [Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products](#)
- 6797265- [Deleted adenovirus vectors and methods of making and administering the same](#)
- 6818803- [Transgenic plants as an alternative source of lignocellulosic-degrading enzymes](#)
- 6852544- [Rapid quantitative analysis of proteins or protein function in complex mixtures](#)
- 6858425- [Human acid alpha glucosidase gene and bovine alpha-S1 casein gene sequences](#)
- 6867036- [Gene expression by positive feedback activation of a cell type-specific promoter](#)
- 6905827- [Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases](#)
- 6939862- [Method for transferring nucleic acid into striated muscles](#)
- 6946126- [Replicating adenovirus vectors](#)
- 6706867- [DNA array sequence selection](#)
- 6670194- [Rapid quantitative analysis of proteins or protein function in complex mixtures](#)
- 6566099- [Nucleic acid encoding a chimeric polypeptide](#)
- 5981835- [Transgenic plants as an alternative source of lignocellulosic-degrading enzymes](#)
- 6005004- [Lipophilic-polycationic delivery systems](#)
- 6066626- [Compositions and method for treating lysosomal storage disease](#)
- 6083725- [Tranfected human cells expressing human .alpha.-galactosidase A protein](#)
- 6118045- [Lysosomal proteins produced in the milk of transgenic animals](#)
- 6303300- [Poly \(organo\) phosphazenes for use in synthetic transfection systems](#)
- 6328958- [Deleted adenovirus vectors and methods of making and administering the same](#)
- 6395884- [Therapy for .alpha.-galactosidase a deficiency](#)
- 6472212- [Methods and compositions for genetically modifying primate bone marrow cells](#)
- 6528315- [Method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor](#)
- 7018628- [Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates](#)
- 7026121- [Methods and compositions for diagnosing and monitoring transplant rejection](#)
- 7265085- [Glycoconjugation methods and proteins/peptides produced by the methods](#)
- 7276475- [Remodeling and glycoconjugation of peptides](#)
- 7297511- [Interferon alpha: remodeling and glycoconjugation of interferon alpha](#)
- 7329422- [Pharmaceutical compositions](#)
- 7351410- [Treatment of Pompe's disease](#)
- 7358086- [Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products](#)
- 7361481- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7378231- [Diagnosis of lysosomal storage disorders using saposins and other markers](#)
- 7396811- [Subcellular targeting of therapeutic proteins](#)
- 7399613- [Sialic acid nucleotide sugars](#)
- 7265084- [Glycopegylation methods and proteins/peptides produced by the methods](#)
- 7235358- [Methods and compositions for diagnosing and monitoring transplant rejection](#)
- 7226903- [Interferon beta: remodeling and glycoconjugation of interferon beta](#)
- 7034010- [Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders](#)
- 7115391- [Production of recombinant AAV using adenovirus comprising AAV rep/cap genes](#)
- 7122354- [Nucleic acid encoding a chimeric polypeptide](#)
- 7125843- [Glycoconjugates including more than one peptide](#)
- 7138371- [Remodeling and glycoconjugation of peptides](#)
- 7157277- [Factor VIII remodeling and glycoconjugation of Factor VIII](#)
- 7173003- [Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF](#)

- 7179617- [Factor IX: remodeling and glycoconjugation of Factor IX](#)
- 7198776- [Metal complex compounds](#)
- 7214660- [Erythropoietin: remodeling and glycoconjugation of erythropoietin](#)
- 7402308- [Method of delivering genes to the central nervous system of a mammal](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

